Monday, May 17, 2021 Daily Archives

Ins & outs: Catalent’s CFO heads to Zoetis

by

Catalent has named Thomas Castellano as its chief financial officer. Meanwhile, there are changes at Attralus Therapeutics and Centessa. Sit back, relax, and enjoy BioProcess Insider’s Ins & Outs. First up in our Ins & Outs feature is Catalent, which has named Thomas Castellano to succeed Wetteny Joseph as chief financial officer, effective June 1. Castellano currently serves at the contract development manufacturing organization (CDMO) as global vice president of operational finance. Castellano joined the firm in 2008 as director…

May 17, 2021

Merck: COVID-related work helped German firm grow revs in Q1

by

COVID-19 will continue to drive growth according to Merck KGaA, which says demand from vaccine makers helped its life science business revenue grow 20.4% to € 2.1 billion in Q1. The German drug and processing tech firm unveiled its results for the first quarter this week, explaining that group sales increased 6% to € 4.6 billion ($5.6 billion) “mainly thanks to the high organic growth of the Life Science business.†Merck’s process solutions business – the part of the life sciences…

May 17, 2021

PerkinElmer set to acquire Nexcelom Bioscience for $260m

by

PerkinElmer will bolster its preclinical portfolio and cell and gene therapy manufacturing capabilities through the acquisition of Nexcelom. PerkinElmer will pay  $260 million in cash, with the transaction anticipated to close in the second quarter of 2021. “Nexcelom’s leading cell counting and analysis solutions are a strong complement to PerkinElmer’s preclinical high content imaging, cell painting and automation portfolio for drug discovery and will enhance our ability to support customers in the manufacturing QA/QC phase of cell and gene and…

May 17, 2021